Literature DB >> 7213529

The effect of enzyme induction on the metabolism of disopyramide in man.

M L Aitio, L Mansury, E Tala, M Haataja, A Aitio.   

Abstract

1 The effects of rifampicin, phenytoin, and disopyramide treatments on the metabolism of disopyramide were studied in patients and volunteers. 2 Rifampicin treatment markedly increased the metabolism of disopyramide. 3 Phenytoin had effects similar to those of rifampicin. The effect subsided in 2 weeks after stopping the treatment. 4 The metabolism of disopyramide seemed fastest in the patient group with the higher dose of disopyramide. Both in patients and volunteers a significant increase occurred in the urinary mono-N-dealkyldisopyramide/disopyramide ratio during the first week of disopyramide therapy. This change can partly be due to pharmacokinetic differences between disopyramide and its metabolite. The inducing effect of disopyramide remained uncertain.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7213529      PMCID: PMC1401616          DOI: 10.1111/j.1365-2125.1981.tb00535.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  The pharmacokinetics of Norpace.

Authors:  A Karim
Journal:  Angiology       Date:  1975-01       Impact factor: 3.619

2.  The excretion of D-glucaric acid in the urine of human volunteers following the administration of disopyramide.

Authors:  D Rycroft; J W Daniel
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

3.  Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.

Authors:  P H Hinderling; E R Garrett
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

4.  The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.

Authors:  J L Cunningham; D D Shen; I Shudo; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

5.  Disopyramide.

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1979-04-26       Impact factor: 91.245

6.  Induction of disopyramide N-dealkylation by phenobarbital and disopyramide in rat liver.

Authors:  M L Aitio; A Aitio
Journal:  Arch Int Pharmacodyn Ther       Date:  1979-05

7.  Some effects of disopyramide and its N-dealkylated metabolite on isolated nerve and cardiac muscle.

Authors:  A M Grant; R J Marshall; S I Ankier
Journal:  Eur J Pharmacol       Date:  1978-06-15       Impact factor: 4.432

8.  Production of endogenous D-glucaric acid and oxidative N-demethylation of amidopyrine in man: lack of correlation.

Authors:  K J Freundt
Journal:  Int J Clin Pharmacol Biopharm       Date:  1979-03

9.  Enhanced metabolism and diminished efficacy of disopyramide by enzyme induction?

Authors:  M L Aitio; T Vuorenmaa
Journal:  Br J Clin Pharmacol       Date:  1980-02       Impact factor: 4.335

10.  Responses of the D-glucuronic acid pathway in rat tissues to treatment with tetrachlorodibenzodioxin.

Authors:  M Marselos; R Törrönen; A Aitio
Journal:  Xenobiotica       Date:  1978-07       Impact factor: 1.908

View more
  20 in total

1.  Rifampicin lowers plasma concentrations of propafenone and its antiarrhythmic effect.

Authors:  J M Castel; E Cappiello; D Leopaldi; R Latini
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

Review 2.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 3.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 4.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

Review 5.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 6.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of disopyramide.

Authors:  L A Siddoway; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

8.  Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man.

Authors:  J Hasselström; M Enquist; J Hermansson; R Dahlqvist
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 9.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 10.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.